Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15161665 | 0.88 | IDO1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL5429223 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL2533000 | 0.87 | CYP2A6 (0.58) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL29644219 | 0.87 | CYP2A6 (0.58) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL29953288 | 0.84 | PIM1 (0.47) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL29935857 | 0.77 | CAPN1 (0.59) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL208051 | 0.77 | CAPN1 (0.59) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL29954011 | 0.77 | ALDH1A1 (0.62) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL2535952 | 0.76 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL29609054 | 0.75 | KIF11 (0.49) | ALDH1A1CYP1A2IDO1KDM4EKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629988-A1 | DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER AND INFECTIONS | Centre National de la Recherche Scientifique (FR) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121072-A1 | DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER AND INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-06-13 | — | — | WO | disclosed |
| CN-115974839-B | AChE/SERT double-target inhibitor and preparation method and application thereof | 珠海市藤栢医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023116915-A1 | ACHE/SERT DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 珠海市藤栢医药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-115974839-A | AChE/SERT double-target-point inhibitor and preparation method and application thereof | 珠海市藤栢医药有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| EP-2850083-B1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | JANSSEN PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | ALDH1A1 516/4885CYP1A2 88/4885CYP2C19 39/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | ALDH1A1 961/4885CYP1A2 153/4885CYP2C19 41/4885 |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | ALDH1A1 903/4885CYP1A2 276/4885CYP2C19 9/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | ALDH1A1 600/4885CYP1A2 942/4885CYP2C19 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.